Cargando…
Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid
Barth syndrome is a rare and potentially fatal X-linked disease characterized by cardiomyopathy, skeletal muscle weakness, growth delays, and cyclic neutropenia. Patients with Barth syndrome are prone to high risk of mortality in infancy and the development of cardiomyopathy with severe weakening of...
Autor principal: | Sabbah, Hani N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388406/ https://www.ncbi.nlm.nih.gov/pubmed/34623544 http://dx.doi.org/10.1007/s10741-021-10177-8 |
Ejemplares similares
-
Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide
por: Sabbah, Hani N.
Publicado: (2020) -
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome
por: Hornby, Brittany, et al.
Publicado: (2022) -
Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data
por: Van den Eynde, Jef, et al.
Publicado: (2023) -
Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide
por: Sabbah, Hani N., et al.
Publicado: (2018) -
Barth Syndrome Cardiomyopathy: An Update
por: Pang, Jing, et al.
Publicado: (2022)